| A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy (NCT07688291) | Beijing GoBroad Hospital | 2026-06-30 |
| A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases (NCT07593911) | Beijing GoBroad Hospital | 2026-06-01 |
| Early Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of STR-P005 (NCT07605637) | Beijing GoBroad Hospital | 2026-06-01 |
| A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma (NCT07520357) | Beijing GoBroad Hospital | 2026-04-30 |
| Safety and Efficacy of CT0494BCP in Participants With Advanced Gastric/Esophagogastric Junction Adenocarcinoma (NCT07538856) | Beijing GoBroad Hospital | 2026-04-01 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (NCT06947473) | Beijing GoBroad Hospital | 2026-03-18 |
| Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial (NCT06326008) | Beijing GoBroad Hospital | 2026-03-15 |
| Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer (NCT07329894) | Beijing GoBroad Hospital | 2026-02-01 |
| TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (NCT07242417) | Beijing GoBroad Hospital | 2025-12-18 |
| To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma (NCT07179484) | Beijing GoBroad Hospital | 2025-10-22 |
| A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases (NCT07167537) | Beijing GoBroad Hospital | 2025-10-01 |
| Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma (NCT07198373) | Beijing GoBroad Hospital | 2025-09-20 |
| Exploratory Clinical Study on the Safety of STR-P004 (NCT07143617) | Beijing GoBroad Hospital | 2025-09-16 |
| Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT07093411) | Beijing GoBroad Hospital | 2025-08-05 |
| A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies (NCT07070323) | Beijing GoBroad Hospital | 2025-07-09 |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma (NCT07014540) | Beijing GoBroad Hospital | 2025-06-20 |
| CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas (NCT07022964) | Beijing GoBroad Hospital | 2025-06-01 |
| A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases (NCT06980597) | Beijing GoBroad Hospital | 2025-06-01 |
| Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration (NCT07003555) | Beijing GoBroad Hospital | 2025-05-25 |
| Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration (NCT07003568) | Beijing GoBroad Hospital | 2025-05-25 |
| A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer (NCT06951243) | Beijing GoBroad Hospital | 2025-05-06 |
| CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH (NCT06947460) | Beijing GoBroad Hospital | 2025-04-18 |
| CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas (NCT06925464) | Beijing GoBroad Hospital | 2025-04-01 |
| One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL (NCT06618313) | Beijing GoBroad Hospital | 2025-03-27 |
| CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) (NCT06822881) | Beijing GoBroad Hospital | 2025-02-20 |
| Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia (NCT06890494) | Beijing GoBroad Hospital | 2025-01-18 |
| A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia (NCT06729320) | Beijing GoBroad Hospital | 2024-12-01 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases (NCT06688799) | Beijing GoBroad Hospital | 2024-11-23 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus (NCT06585514) | Beijing GoBroad Hospital | 2024-10-17 |
| Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer (NCT06433609) | Beijing GoBroad Hospital | 2024-08-05 |
| CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies (NCT06316856) | Beijing GoBroad Hospital | 2024-06-18 |
| CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction (NCT06389305) | Beijing GoBroad Hospital | 2024-05-27 |
| Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients (NCT06343090) | Beijing GoBroad Hospital | 2024-04-12 |
| Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia (NCT06326021) | Beijing GoBroad Hospital | 2024-04-02 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies (NCT06316427) | Beijing GoBroad Hospital | 2024-03-22 |